Department of Hepato-Biliary-Pancreatic Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
J Hepatobiliary Pancreat Sci. 2022 Nov;29(11):1153-1155. doi: 10.1002/jhbp.1215. Epub 2022 Aug 8.
Tanaka et al. previously reported a case in which nivolumab for recurrent occupational cholangiocarcinoma resulted in complete response persisting for 26 months after discontinuation. Afterward, in that clinical trial, nivolumab was administered to two patients for recurrence. Both patients achieved complete response, suggesting that nivolumab is effective for occupational cholangiocarcinoma.
此前，田中等人曾报道过一例复发性职业性胆管癌患者，在停止使用纳武利尤单抗后 26 个月仍持续完全缓解。此后，在该临床试验中，纳武利尤单抗用于两名复发性胆管癌患者。两名患者均达到完全缓解，表明纳武利尤单抗对职业性胆管癌有效。
